Risks for INVACARE CORP (IVC)

Here are some interesting risks from the recent filings of INVACARE CORP. Our algorithms work hard to highlight risks unique to this company.

The company is subject to a consent decree of injunction ("consent decree") with the U.S. Food and Drug Administration (“FDA”), the effects of which have been, and continue to be, costly to the company and could result in continued adverse consequences to the company's business.

Being in the health care industry, the company is subject to extensive government regulation, and if the company fails to comply with applicable health care laws or regulations, the company could suffer severe civil or criminal sanctions or may be required to make significant changes to the company’s operations that could have a material adverse effect on the company’s results of operations.

The company’s products are subject to recalls, which could be costly and harm the company’s reputation and business.

The adoption of healthcare reform and other legislative developments in the U.S. may adversely affect the company’s business, results of operations and/or financial condition.

If the company’s business transformation efforts are ineffective, the company’s strategic goals, business plans, financial performance or liquidity could be negatively impacted.